E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with active Rheumatoid Artrhitis (DAS28 > 3.2) despite DMARD therapy |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10040107 |
E.1.2 | Term | Seropositive rheumatoid arthritis |
E.1.2 | System Organ Class | 100000004859 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary parameter of interest is the proportion of patients who reach low disease activity according to the DAS28 (DAS28 < 3.2) during the first 12 weeks of study participation according their baseline CNS activity measured by functional MRI. |
|
E.2.2 | Secondary objectives of the trial |
To compare clinical responses to Certolizumab-Pegol in RA patients with high and low CNS activity in the functional MRI to placebo responses |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Subjects must have a diagnosis of Rheumatoid Arthritis (RA), fulfilling the new ACR/EULAR classification criteria 2010 with disease duration for at least 24 weeks.
• Active RA with a DAS28 of >3.2
• ≥3 swollen and/or tender joints of the hands
• Subjects must be DMARD-IR (inadequate responder)
• Must understand and voluntarily sign an informed consent form including written consent for data protection
• Must be able to adhere to the study visit schedule and other protocol requirements
• Must be aged ≥ 18 years at time of consent
• Glucocorticoids treatment up to 10 mg prednisolon per day will be allowed at study entry
• At screening-visit patients should have been treated without alterations of DMARD therapy (for at least three months) (i.e. Methotrexate) (with or without concomitant use of steroids).
• Must be RF and/or ACPA positive
• ≥ 3 swollen and/or tender joints of the hands
• At screening- visit patients should have been treated
without alterations of therapy for at least three months
with DMARDS (i.e. Methotrexate) with or without
concomitant use of steroids).
• Glucocorticoids treatment up to 10mg prednisolone per
day will be allowed at study entry.
|
|
E.4 | Principal exclusion criteria |
• Individuals not able to understand and follow study protocol and not able to voluntarily sign informed consent
• Individuals not willing to follow study protocol and sign informed consent
• Individuals treated with biological or investigational products before.
• Individuals with claustrophobia, tattoos containing metal, magnetic endoprotheses, surgery on bone in between a time interval < 3 months, patients in any condition not allowing for MRI scan.
• Current treatment with MMF or preparations still in development.
• Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
• Any other autoimmune or inflammatory disease such as Psoriasis, SLE, PSS, MCTD, SpA, Behcet disease, vasculitis, autoimmune hepatitis or fibromyalgia
• Participation in another phase 1-4 treatment study for RA
• Patients who are younger than 18 years or are incapable to understand the aim, importance and consequences of the study and to give legal informed consent
• Pregnant or lactating female (Women with child bearing potential have to use a highly effective contraceptive measure (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices - IUDs) and continue its use for the time of exposure to the drug as required). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) are not acceptable
• Patients who possibly are dependent on the Principal Investigator or investigator
• Patients with serious or chronic infections within the previous 3 months
• Opportunistic infections within the 6 months before screening
• Cancer within the 5 years before screening (with the exception of treated and cured squamous or basal cell carcinoma of the skin)
• History of severe congestive heart failure
• Current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal (a.e.diverticulitis), endocrine, pulmonary, cardiac, neurologic or cerebral disease
• Transplanted organ (with the exception of corneal transplantation done more than 3 months before screening)
• Evidence of active tuberculosis
• Evidence of chronic or active hepatitis B or C
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of patients who reach low disease activity according to the DAS28 (DAS28 < 3.2) during the first 12 weeks of study participation according their screening CNS activity measured by functional MRI.
Expected:
• Group 1 (high voxel count treated with Certolizumab
Pegol): 80%)
• Group 2 (low voxel count treated with Certolizumab
Pegol): 40%)
• Group 3 (high or low voxel count treated with placebo):
20%.)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Proportion of subjects in each treatment group reaching remission (defined as DAS28 < 2.6) after 2 12 and 24 weeks
• Proportion of subjects in each treatment group reaching low disease activity (defined as DAS 28 <3.2) after 24 weeks
• Mean and median DAS28 after 2 12 and 24 weeks
• Proportion of subjects in each treatment group reaching HAQ of zero after 12 and 24 weeks
• Mean and median HAQ after 2 12 and 24 weeks
• Mean and median SF-36 after 2 12 and 24 weeks
• Proportion of subjects in each treatment group with normal functional MRI after screening, week 12 and 24 weeks
• Proportion of subjects in each treatment group with normal functional MRI after screening, 12 and 24 weeks
• Mean and median ultrasound synovitis score after 2, 12 and 24 weeks
• Mean and median ultrasound synovitis score after 2, 12 and 24 weeks
• Mean and median area of BOLD signal after screening, week 12 and 24 weeks
• Type, frequency, severity and relationship of adverse events, serious adverse events or suspected unexpected serious adverse reactions to drugs used in this study
• Number of subjects who prematurely discontinue Certolizumab-Pegol due to any adverse event
• Mean and median changes of hormones after 2, 12 and 24 weeks compared to fMRI results
• Mean and median changes of cytokines after 2, 12 and 24 weeks compared to fMRI results
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Germany |
Portugal |
Serbia |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Pregnancy, any event with elevated risk of interaction with immunosuppressive therapy such as myocardial infarction, pulmonary embolism, apoplexy; medical emergencies requiring immediate stationary treatment and / or surgery (severe traffic accident, ileus, etc.), and infectious diseases requiring anti-inflammatory therapy risking interaction with immunosuppressive therapy (compare composition of medical interactions). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |